定制帕多瓦2型糖尿病模拟器,以在目标人群中提供治疗指导
IEEE transactions on bio-medical engineering
|January 10, 2024
概括
这项研究通过使用临床数据,适应了帕多瓦2型糖尿病模拟器 (T2DS) 的胰岛素素原始患者. 调整后的模拟器准确地重现了临床结果,提高了T2D治疗的优化.
科学领域:
- 生物医学工程 生物医学工程
- 计算生物学 计算生物学
- 内分泌学 在内分泌学.
背景情况:
- 帕多瓦2型糖尿病模拟器 (T2DS) 对于优化治疗非常有价值,但仅限于早期患者.
- 在以前没有胰岛素或晚期2型糖尿病 (T2D) 患者群体中的模拟更具有临床相关性,但很难在实验上实现.
- 现有的T2DS需要复杂,昂贵的实验,将其应用限制在特定的T2D亚群中.
研究的目的:
- 开发和验证一种方法,利用已公布的临床数据,将T2DS适应于各种T2D亚群.
- 扩展T2DS以模拟之前未使用胰岛素的T2D患者开始胰岛素治疗.
- 增强T2DS的实用性,以提供个性化的T2D治疗指导.
主要方法:
- 来自目标T2D人群的文献数据被用于确定T2DS模型参数.
- 创建了一个虚拟的前不曾使用胰岛素的T2D受试者队列 (inC1),结合了基底胰岛素降解剂 (IDeg) 模型.
- 通过模拟IDeg疗法启动并将结果与临床数据进行比较来验证量身定制的T2DS,并使用第二个队列 (inC2) 进行进一步验证.
主要成果:
- 在对比临床数据与inC1和inC1与inC2.2时,模拟没有显示出快速血葡萄糖或IDeg剂量的统计学上显著差异.
- 调整后的T2DS成功地重现了涉及从未使用过胰岛素的T2D患者的临床研究的关键发现.
- 模型适应在模拟和真实世界的临床试验结果之间产生了可比的结果.
结论:
- 拟议的方法有效调整T2DS针对特定的T2D亚群,如以前没有胰岛素的患者.
- 调整后的T2DS准确地反映了临床结果,支持其在治疗指南中的使用.
- 这种方法扩大了T2DS的适用性,以优化T2D管理在不同患者配置文件中.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Insulin: Dosing Regimen and Adverse Effects
175
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
175
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204


